See more : Mirae Asset Securities Co. Ltd. (006805.KS) Income Statement Analysis – Financial Results
Complete financial analysis of RespireRx Pharmaceuticals Inc. (RSPI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of RespireRx Pharmaceuticals Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- BlackRock MuniVest Fund, Inc. (MVF) Income Statement Analysis – Financial Results
- Chu Yu Hsiang Co., Ltd (2760.TWO) Income Statement Analysis – Financial Results
- Taylor Maritime Investments Limited (TMIP.L) Income Statement Analysis – Financial Results
- Migdal Insurance and Financial Holdings Ltd. (MGDL.TA) Income Statement Analysis – Financial Results
- Clarus Corporation (CLAR) Income Statement Analysis – Financial Results
RespireRx Pharmaceuticals Inc. (RSPI)
About RespireRx Pharmaceuticals Inc.
RespireRx Pharmaceuticals Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. It has two drug platforms comprising ResolutionRx, a pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the CB1 and CB2 endocannabinoid receptors for use in chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS and obstructive sleep apnea; and EndeavourRx, a neuromodulators platform that comprises AMPAkines program, including proprietary compounds that are positive allosteric modulators (PAMs) of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptors to promote neuronal function, and GABAkines program, including proprietary compounds that are PAMs of GABAA receptors. The company's lead ampakine, CX1739, which has completed Phase II clinical studies for opioid-induced respiratory depression, as well as for central sleep apnea. It is also developing CX717, CX1739, and CX1942 that have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and various orphan indications. The company was formerly known as Cortex Pharmaceuticals, Inc. and changed its name to RespireRx Pharmaceuticals Inc. in December 2015. RespireRx Pharmaceuticals Inc. was incorporated in 1987 and is headquartered in Glen Rock, New Jersey.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 86.92K | 61.67K | 0.00 | 48.31K | 3.11M | 10.47M | 11.00K | 0.00 | 25.00K | 1.18M | 2.58M | 6.97B | 5.23M | 6.43M | 4.44M | 5.51M | 3.15M | 130.00K | 0.00 | 0.00 | 100.00K | 100.00K | 2.60M | 1.00M | 100.00K | 100.00K | 100.00K | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.17K | 6.95K | 1.71K | 591.77 | 206.91 | 826.70 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -172.76K | 0.00 | 0.00 | 0.00 | 0.00 | 4.10M | 2.80M | 1.80M | 2.10M | 1.80M | 2.40M | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -5.17K | -6.95K | 85.21K | 61.08K | -206.91 | 47.48K | 3.11M | 10.47M | 11.00K | 0.00 | 25.00K | 1.18M | 2.58M | 6.97B | 5.23M | 6.43M | 4.44M | 5.68M | 3.15M | 130.00K | 0.00 | 0.00 | -4.00M | -2.70M | 800.00K | -1.10M | -1.70M | -2.30M | 100.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 98.04% | 99.04% | 0.00% | 98.29% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 103.14% | 100.00% | 100.00% | 0.00% | 0.00% | -4,000.00% | -2,700.00% | 30.77% | -110.00% | -1,700.00% | -2,300.00% | 100.00% | 0.00% |
| Research & Development | 429.53K | 702.04K | 638.28K | 599.33K | 688.29K | 1.73M | 3.18M | 1.71M | 591.77K | 206.91K | 826.70K | 2.19M | 3.74M | 4.60M | 10.78M | 9.33M | 13.26M | 11.18M | 6.12B | 3.80M | 5.04M | 4.41M | 3.90M | 3.38M | 4.01M | 3.38M | 2.68M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 110.00K |
| General & Administrative | 1.15M | 1.86M | 2.68M | 1.14M | 1.49M | 2.52M | 5.30M | 3.62M | 3.82M | 932.97K | 1.95M | 3.19M | 4.55M | 3.74M | 4.26M | 4.32M | 3.38B | 3.39B | 2.29B | 2.62B | 2.44B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 220.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -397.00 | -82.00 | -3.37B | -3.39B | 0.00 | -2.62B | -2.44B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.15M | 1.86M | 2.68M | 1.14M | 1.49M | 2.52M | 5.30M | 3.62M | 3.82M | 932.97K | 1.95M | 3.19M | 4.55M | 3.74M | 4.26M | 4.32M | 4.62M | 3.56M | 2.29B | 2.62M | 2.44M | 2.43M | 1.81M | 1.40M | 1.58M | 1.71M | 1.64M | 2.90M | 2.00M | 1.40M | 1.30M | 900.00K | 0.00 | 1.30M | 220.00K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.61M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 167.62M | 1.11B | 0.00 | 0.00 | 0.00 | 172.76K | 0.00 | 0.00 | 0.00 | 0.00 | 200.00K | 200.00K | 200.00K | 100.00K | 100.00K | 100.00K | 0.00 | 10.00K |
| Operating Expenses | 1.58M | 2.56M | 3.32M | 1.74M | 2.18M | 4.25M | 8.47M | 5.33M | 4.42M | 1.14M | 2.77M | 5.38M | 8.29M | 8.33M | 15.04M | 13.65M | 17.88M | 14.74M | 9.51B | 6.42M | 7.49M | 6.84M | 5.88M | 4.78M | 5.59M | 5.09M | 4.32M | 3.10M | 2.20M | 1.60M | 1.40M | 1.00M | 100.00K | 1.30M | 340.00K |
| Cost & Expenses | 1.58M | 2.56M | 3.32M | 1.74M | 2.18M | 4.25M | 8.47M | 5.33M | 4.42M | 1.14M | 2.77M | 5.38M | 8.29M | 8.33M | 15.04M | 13.65M | 17.88M | 14.74M | 9.51B | 6.42M | 7.49M | 6.84M | 5.71M | 4.78M | 5.59M | 5.09M | 4.32M | 7.20M | 5.00M | 3.40M | 3.50M | 2.80M | 2.50M | 1.30M | 340.00K |
| Interest Income | 603.82 | 724.77 | 545.68 | 404.66 | 0.00 | 0.00 | 8.00 | 9.00 | 0.00 | 0.00 | 92.00 | 1.86K | -8.50K | 16.58K | 443.06K | 678.05K | 645.82K | 637.37K | 0.00 | 0.00 | 72.14K | 254.86K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 603.82K | 724.77K | 545.68K | 404.66K | 136.24K | 102.23K | 586.35K | 902.70K | 117.31K | 56.34K | 196.98K | 4.02K | 1.63M | -8.44M | -14.60M | -12.97M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -4.93M | -4.16M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 30.00K |
| Depreciation & Amortization | 80.45K | 2.56M | 3.32M | 1.74M | 5.17K | 5.17K | 6.95K | 7.12K | 1.66K | -7.22K | 115.86K | 106.97K | 112.48K | 186.94K | 164.89K | 126.85K | 110.79K | 125.98K | 0.00 | 155.85K | 153.18K | 149.48K | 172.76K | 197.66K | 201.66K | 198.06K | 230.22K | -200.00K | -200.00K | -200.00K | -100.00K | 100.00K | 100.00K | 20.00K | 50.00K |
| EBITDA | -1.50M | -963.75K | -2.43M | -378.53K | -2.46M | -4.24M | -8.46M | -5.05M | -2.59M | -1.14M | -7.26M | -2.15M | 2.29M | -8.25M | -14.43M | -12.84M | -15.94M | -11.50M | -2.54B | -1.03M | -901.60K | -2.25M | -30.01K | -1.43M | -5.26M | -4.89M | -4.09M | -7.10M | -5.00M | -600.00K | -2.50M | -2.60M | -2.30M | -1.20M | -290.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -6,020.17% | -7,057.06% | 0.00% | -5,400.72% | -69.18% | 21.99% | -72,951.27% | 0.00% | -54,081.46% | -1,408.95% | -463.68% | -36.43% | -19.75% | -14.02% | -50.61% | -0.54% | -45.45% | -4,046.29% | 0.00% | 0.00% | -7,100.00% | -5,000.00% | -23.08% | -250.00% | -2,800.00% | -2,500.00% | -1,300.00% | 0.00% |
| Operating Income | -1.58M | -2.56M | -3.32M | -1.74M | -2.18M | -4.25M | -8.47M | -5.24M | -4.35M | -1.14M | -7.33M | -2.26M | 2.18M | -8.33M | -15.04M | -13.65M | -16.70M | -12.16M | -2.54B | -1.19M | -1.05M | -2.40M | -202.77K | -1.63M | -5.46M | -5.09M | -4.32M | -6.80M | -4.70M | -800.00K | -2.40M | -2.60M | -2.20M | -1.22M | -340.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -6,028.37% | -7,059.75% | 0.00% | -15,177.09% | -72.62% | 20.83% | -75,770.52% | 0.00% | -54,588.86% | -1,418.36% | -471.78% | -36.43% | -22.73% | -16.40% | -53.98% | -3.68% | -51.72% | -4,201.41% | 0.00% | 0.00% | -6,800.00% | -4,700.00% | -30.77% | -240.00% | -2,600.00% | -2,200.00% | -1,220.00% | 0.00% |
| Total Other Income/Expenses | -523.37K | -585.71K | -986.08K | -378.53K | -415.27K | -44.07K | -757.87K | -722.28K | 1.65M | -63.56K | -240.34K | 6.95K | -553.30K | -106.60K | 443.06K | 678.05K | 645.82K | 554.38K | 0.00 | 14.51K | 72.14K | 2.40M | 5.37K | 8.48K | 203.88K | 155.62K | 163.06K | 200.00K | 300.00K | 0.00 | 100.00K | 200.00K | 200.00K | 100.00K | 20.00K |
| Income Before Tax | -2.10M | -3.14M | -4.30M | -2.12M | -2.59M | -4.29M | -9.23M | -5.96M | -2.71M | -1.20M | -7.57M | -2.25M | 1.63M | -8.44M | -14.60M | -12.97M | -16.05M | -11.61M | 0.00 | -1.17M | -982.64K | -2.67M | -197.40K | -1.62M | -5.26M | -4.93M | -4.16M | -6.80M | -4.70M | -800.00K | -2.40M | -2.60M | -2.20M | -1.20M | -320.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -6,859.37% | -4,390.57% | 0.00% | -15,674.60% | -72.40% | 15.55% | -76,739.58% | 0.00% | -51,876.65% | -1,363.51% | -450.28% | 0.00% | -22.46% | -15.28% | -60.17% | -3.58% | -51.45% | -4,044.58% | 0.00% | 0.00% | -6,800.00% | -4,700.00% | -30.77% | -240.00% | -2,600.00% | -2,200.00% | -1,200.00% | 0.00% |
| Income Tax Expense | -80.45K | 724.77K | 545.68K | 404.66K | 279.02K | 44.07K | 757.87K | 722.28K | -1.65M | 7.22K | 4.85M | 2.25M | -1.63M | 8.44M | 14.60M | 12.97M | 16.05M | 11.61M | 0.00 | 1.17M | 982.64K | 2.67M | 197.40K | 1.62M | 5.26M | 4.93M | 4.16M | 6.80M | 4.70M | 800.00K | 2.40M | 2.60M | 2.20M | 1.20M | -50.00K |
| Net Income | -3.97M | -3.87M | -4.85M | -2.52M | -2.59M | -4.29M | -9.23M | -5.96M | -2.71M | -1.20M | -7.57M | -2.25M | 1.63M | -8.44M | -14.60M | -12.97M | -16.05M | -11.61M | 0.00 | -1.17M | -982.64K | -2.67M | -197.40K | -1.62M | -5.26M | -4.93M | -4.16M | -6.80M | -4.70M | -800.00K | -2.40M | -2.60M | -2.20M | -1.20M | -270.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -6,859.37% | -4,390.57% | 0.00% | -15,674.60% | -72.40% | 15.55% | -76,739.58% | 0.00% | -51,876.65% | -1,363.51% | -450.28% | 0.00% | -22.46% | -15.28% | -60.17% | -3.58% | -51.45% | -4,044.58% | 0.00% | 0.00% | -6,800.00% | -4,700.00% | -30.77% | -240.00% | -2,600.00% | -2,200.00% | -1,200.00% | 0.00% |
| EPS | -0.04 | -0.04 | -0.19 | -6.45 | -7.73 | -17.75 | -49.51 | -50.40 | -45.65 | -27.11 | -226.92 | -91.62 | 65.00 | -491.81 | -997.19 | -1.00K | -1.52K | -1.15K | 0.00 | -226.37 | -191.10 | -523.36 | -40.62 | -393.08 | -1.78K | -1.94K | -2.07K | -3.67K | -3.09K | -779.73 | -2.56K | -3.21K | -2.74K | -1.93K | -27.00 |
| EPS Diluted | -0.04 | -0.04 | -0.19 | -6.45 | -7.73 | -17.75 | -49.51 | -50.40 | -45.65 | -27.11 | -226.92 | -91.62 | 65.00 | -491.81 | -997.19 | -1.00K | -1.52K | -1.15K | 0.00 | -226.37 | -177.31 | -523.36 | -40.62 | -393.08 | -1.78K | -1.94K | -2.07K | -3.67K | -3.09K | -779.73 | -2.56K | -3.21K | -2.74K | -1.93K | -27.00 |
| Weighted Avg Shares Out | 111.32M | 88.35M | 25.86M | 390.85K | 335.11K | 241.83K | 186.40K | 118.29K | 59.31K | 44.32K | 33.37K | 24.61K | 22.67K | 17.16K | 14.64K | 12.96K | 10.57K | 10.05K | 7.13K | 5.19K | 5.14K | 5.11K | 4.86K | 4.13K | 2.95K | 2.54K | 2.01K | 1.85K | 1.52K | 1.03K | 937.00 | 810.00 | 802.00 | 621.00 | 10.00K |
| Weighted Avg Shares Out (Dil) | 111.32M | 88.35M | 25.86M | 390.85K | 335.11K | 241.83K | 186.40K | 118.29K | 59.31K | 44.32K | 33.37K | 24.61K | 22.67K | 17.16K | 14.64K | 12.96K | 10.57K | 10.05K | 7.13K | 5.19K | 5.54K | 5.11K | 4.86K | 4.13K | 2.95K | 2.54K | 2.01K | 1.85K | 1.52K | 1.03K | 937.00 | 810.00 | 802.00 | 621.00 | 10.00K |
RespireRx Pharmaceuticals subsidiary inks MSA for dronabinol manufacturing
RespireRx Pharmaceuticals (OTC:RSPI) Ltd and its ResolutionRx subsidiary announced that it has entered into a Master Services Agreement (MSA) with Australia's Ab Initio Pharma Pty Ltd (Ab Initio), under which Ab Initio will manufacture, formulate, test and supply ResolutionRx with therapeutic drugs...
RespireRx Pharmaceuticals Inc.'s Subsidiary ResolutionRx Ltd Enters into Master Services Agreement for Dronabinol Manufacturing and Related Services
Glen Rock, N.J., Oct. 12, 2023 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Market: RSPI) (“RespireRx” or the “Company”), focused on the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling,...
RespireRx to transfer cannabinoid research program to Australian subsidiary ResolutionRx
RespireRx Pharmaceuticals (OTC:RSPI) shares rose on Wednesday morning after it announced that it has entered into agreements with its Australian subsidiary ResolutionRx to transfer RespireRx's pharmaceutical cannabinoid program to ResolutionRx and establish it as an operating company. Once RespireRx has...
RespireRx Pharmaceuticals Inc. and ResolutionRx Ltd Enter into Bilateral Agreements to Establish ResolutionRx Ltd as an Operating Company
Glen Rock, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC. Pink Market: RSPI) (“RespireRx”), focused on the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, and ResolutionRx Ltd...
RespireRx Pharmaceuticals' Australia cannabis subsidiary inks LOI securing $3.1M investment
RespireRx Pharmaceuticals (OTC:RSPI) Inc subsidiary ResolutionRx Ltd entered into a binding letter of intent last week with Cantheon Capital, in which the latter would help fund the former's clinical trial research and development. The letter describes a total investment of $3.125...
RespireRx Pharmaceuticals highlights analogs of its anti-seizure treatment in scientific publications
RespireRx Pharmaceuticals (OTC:RSPI) Inc has announced the publication of four articles describing the pharmacological activity of novel structural analogs of KRM-II-81, the company's lead anti-GABAkine. Like RespireRx's KRM-II-81, the analogs enhance GABAergic neurotransmission and function as orally bioavailable anti-seizure agents...
RespireRx Pharmaceuticals appoints Joseph Siegelbaum as independent director on its board
RespireRx Pharmaceuticals (OTC:RSPI) Ltd has announced the appointment of Joseph Siegelbaum to the company's board as an independent director, effective March 22, 2023. The biopharma firm said Siegelbaum, a former partner at the law firm of Goodwin Procter LLP in...
RespireRx Pharmaceuticals' Australian subsidiary ResolutionRx enters services agreement with CRO iNGENu
RespireRx Pharmaceuticals (OTC:RSPI) Ltd and its wholly-owned unlisted Australian subsidiary ResolutionRx Ltd jointly announced that ResolutionRx has entered into a services agreement for clinical research and other related services with Melbourne, Australia-based contract research organization (CRO) iNGENu. The companies said in...
RespireRx Pharmaceuticals' Australian subsidiary inks loan agreements to advance R&D for sleep apnea treatment
RespireRx Pharmaceuticals (OTC:RSPI) Inc announced that its recently created Australia-based subsidiary ResolutionRx Ltd has signed a letter of intent (LOI) and term sheet with Radium Capital. The agreements cover a series of planned financing arrangements between the two companies designed...
RespireRx Pharmaceuticals strikes second amendment to its license agreement with the University of Illinois
RespireRx Pharmaceuticals (OTC:RSPI) Inc revealed that the company and the Board of Trustees of University of Illinois (UIL), have agreed to a second amendment to their Exclusive License Agreement. In a statement, RespireRx interim CEO Arnold Lippa said: “As we have...
Source: https://incomestatements.info
Category: Stock Reports